AAVs in Retinal Gene Therapy
Type
Blog Post
...now, 2 decades later, is it finally back in the limelight. On December 19, 2017 the FDA approved Luxturna... brought all these key elements together at the right time and place. But it is the hard work and persistence...immunogenicity is critical when systemic delivery of high doses of vectors are needed. Additionally, AAVs ...ultra-rare ocular diseases are being benched due to the high cost of clinical development. As a result, Luk Vandenberghe...8. Trapani I and Auricchio A., 2018. Seeing the Light after 25 Years of Retinal Gene Therapy. Trends Mol...